BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17583372)

  • 1. Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
    Paghdal KV; Schwartz RA
    J Am Acad Dermatol; 2007 Dec; 57(6):1046-50. PubMed ID: 17583372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus: a therapeutic advance for dermatologic disease.
    Peters T; Traboulsi D; Tibbles LA; Mydlarski PR
    Skin Therapy Lett; 2014; 19(4):1-4. PubMed ID: 25188522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
    Stallone G; Schena A; Infante B; Di Paolo S; Loverre A; Maggio G; Ranieri E; Gesualdo L; Schena FP; Grandaliano G
    N Engl J Med; 2005 Mar; 352(13):1317-23. PubMed ID: 15800227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
    Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
    Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus and regression of Kaposi's sarcoma in immunosuppressed transplant patient.
    Pranteda G; Feliziani G; Grimaldi M; Paleologo G; Pranteda G; Melotti F; Camplone G
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):1022-3. PubMed ID: 18194240
    [No Abstract]   [Full Text] [Related]  

  • 6. Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.
    Ho CM; Huang SF; Hu RH; Ho MC; Wu YM; Lee PH
    Clin Transplant; 2010; 24(1):127-32. PubMed ID: 19919613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of Kaposi's sarcoma in the rapamycin era].
    Gemelli A; Paciolla A; Oliosi F; Basso A; Moscardin R; Tineo MC; Romano P; Alaibac M; Aversa S; Furian L; D'Angelo A; Bonfante L
    G Ital Nefrol; 2009; 26(1):90-3. PubMed ID: 19255968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of post-transplant Kaposi's sarcoma using sirolimus.
    Kolhe N; Mamode N; Van der Walt J; Pattison J
    Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
    Campistol JM; Schena FP
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kaposi's sarcoma after renal transplantation.
    Kanitakis J
    N Engl J Med; 2005 Aug; 353(8):846-7; author reply 846-7. PubMed ID: 16120869
    [No Abstract]   [Full Text] [Related]  

  • 11. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
    Stallone G; Infante B; Grandaliano G; Schena FP; Gesualdo L
    Transpl Int; 2008 Sep; 21(9):825-32. PubMed ID: 18498314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing the risk of posttransplant malignancy.
    Campistol JM
    Transplantation; 2009 Apr; 87(8 Suppl):S19-22. PubMed ID: 19384182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
    Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
    Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin for Kaposi's sarcoma and graft-versus-host disease in bone marrow transplant recipient.
    Marco de F; Infante B; Giovanni S; Gesualdo L
    Transplantation; 2010 Mar; 89(5):633-4. PubMed ID: 20216371
    [No Abstract]   [Full Text] [Related]  

  • 16. Sirolimus for Kaposi's sarcoma.
    Wasywich CA; Croxson MC; van Doornum GJ; Coverdale HA; Ruygrok PN
    J Heart Lung Transplant; 2006 Jun; 25(6):726-9. PubMed ID: 16730579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment.
    Guenova E; Metzler G; Hoetzenecker W; Berneburg M; Rocken M
    Arch Dermatol; 2008 May; 144(5):692-3. PubMed ID: 18490609
    [No Abstract]   [Full Text] [Related]  

  • 19. Sirolimus--challenging current perspectives.
    Buhaescu I; Izzedine H; Covic A
    Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
    Leblanc KG; Hughes MP; Sheehan DJ
    Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.